Personalis (NASDAQ:PSNL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Personalis (NASDAQ:PSNL) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for Personalis’ FY2029 earnings at $0.33 EPS.

PSNL has been the topic of several other reports. Needham & Company LLC decreased their price target on shares of Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a research note on Friday. Lake Street Capital raised their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

Personalis Price Performance

Personalis stock opened at $4.14 on Friday. Personalis has a 12-month low of $1.13 and a 12-month high of $7.20. The stock has a market capitalization of $292.48 million, a P/E ratio of -2.46 and a beta of 1.73. The firm’s 50-day moving average is $5.40 and its two-hundred day moving average is $5.04.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $16.80 million for the quarter, compared to analysts’ expectations of $15.48 million. As a group, analysts forecast that Personalis will post -1.4 EPS for the current year.

Institutional Investors Weigh In On Personalis

Hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Personalis in the fourth quarter worth approximately $28,000. JPMorgan Chase & Co. lifted its position in Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after buying an additional 5,654 shares in the last quarter. Olympiad Research LP acquired a new position in Personalis during the fourth quarter valued at approximately $59,000. Alpine Global Management LLC acquired a new position in Personalis during the fourth quarter valued at approximately $60,000. Finally, SG Americas Securities LLC acquired a new position in Personalis during the fourth quarter valued at approximately $63,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.